MX2023000507A - Inhibidores de la calicreina plasmatica. - Google Patents

Inhibidores de la calicreina plasmatica.

Info

Publication number
MX2023000507A
MX2023000507A MX2023000507A MX2023000507A MX2023000507A MX 2023000507 A MX2023000507 A MX 2023000507A MX 2023000507 A MX2023000507 A MX 2023000507A MX 2023000507 A MX2023000507 A MX 2023000507A MX 2023000507 A MX2023000507 A MX 2023000507A
Authority
MX
Mexico
Prior art keywords
compounds
plasma
inhibitors
callichrein
macular edema
Prior art date
Application number
MX2023000507A
Other languages
English (en)
Spanish (es)
Inventor
Song Yang
Zhiqiang Zhao
Rongze Kuang
Christopher J Sinz
Jacqueline D Hicks
Alan C Cheng
Jianming Bao
Maoqun Tian
Matthew J Lombardo
Zhicai Wu
Jovan Alexander Lopez
Rohan Merchant
Phillip Patrick Sharp
Galen Paul Shearn-Nance
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2023000507A publication Critical patent/MX2023000507A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2023000507A 2020-07-10 2021-07-06 Inhibidores de la calicreina plasmatica. MX2023000507A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063050220P 2020-07-10 2020-07-10
PCT/US2021/040420 WO2022010828A1 (en) 2020-07-10 2021-07-06 Plasma kallikrein inhibitors

Publications (1)

Publication Number Publication Date
MX2023000507A true MX2023000507A (es) 2023-02-09

Family

ID=79552050

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000507A MX2023000507A (es) 2020-07-10 2021-07-06 Inhibidores de la calicreina plasmatica.

Country Status (9)

Country Link
US (1) US12528786B2 (enExample)
EP (1) EP4178620B1 (enExample)
JP (1) JP7773522B2 (enExample)
KR (1) KR20230038526A (enExample)
CN (1) CN116157154B (enExample)
AU (1) AU2021306250A1 (enExample)
CA (1) CA3185597A1 (enExample)
MX (1) MX2023000507A (enExample)
WO (1) WO2022010828A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4210694B1 (en) * 2020-09-10 2025-10-15 Merck Sharp & Dohme LLC Plasma kallikrein inhibitors
WO2024173196A1 (en) * 2023-02-17 2024-08-22 Merck Sharp & Dohme Llc Plasma kallikrein inhibitors
WO2026096331A1 (en) * 2024-10-30 2026-05-07 Merck Sharp & Dohme Llc Plasma kallikrein inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609866B2 (en) 2009-12-18 2013-12-17 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
HRP20221373T1 (hr) 2014-03-07 2023-01-06 Biocryst Pharmaceuticals, Inc. Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
KR102286305B1 (ko) 2014-07-16 2021-08-09 라이프에스씨아이 파마슈티컬스, 인크. 치료적 억제 화합물
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
WO2017001926A2 (en) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc Therapeutic inhibitory compounds
WO2017072020A1 (en) * 2015-10-27 2017-05-04 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
US10640486B2 (en) * 2015-10-27 2020-05-05 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
BR112018008506B8 (pt) 2015-10-29 2023-12-05 Merck Sharp & Dohme Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos
EP3612523B1 (en) 2017-04-21 2021-06-09 Boehringer Ingelheim International GmbH Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
GB201719882D0 (en) * 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
CN113039181B (zh) * 2018-08-16 2024-08-13 勃林格殷格翰国际有限公司 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物
KR102931248B1 (ko) * 2020-06-16 2026-03-03 머크 샤프 앤드 돔 엘엘씨 혈장 칼리크레인 억제제

Also Published As

Publication number Publication date
CN116157154A (zh) 2023-05-23
US12528786B2 (en) 2026-01-20
KR20230038526A (ko) 2023-03-20
WO2022010828A1 (en) 2022-01-13
EP4178620A1 (en) 2023-05-17
CA3185597A1 (en) 2022-01-13
AU2021306250A1 (en) 2023-02-16
EP4178620A4 (en) 2024-08-07
JP7773522B2 (ja) 2025-11-19
CN116157154B (zh) 2026-05-01
US20230348428A1 (en) 2023-11-02
EP4178620B1 (en) 2026-04-01
JP2023533519A (ja) 2023-08-03

Similar Documents

Publication Publication Date Title
MX2023005855A (es) Inhibidores de calicreina plasmatica.
MX2022016321A (es) Inhibidores de la calicreina plasmatica.
JOP20240216A1 (ar) مثبطات kras g12c
PH12021550931A1 (en) New anthelmintic compounds
PH12021552497A1 (en) Enzyme inhibitors
MX2023001689A (es) Inhibidores de bcl-2.
PH12020500257A1 (en) Quinoline derivatives for treating infections with helminths
PH12019502851A1 (en) New azaquinoline derivatives
NO20023688D0 (no) Integrinekspresjonsinhibitorer
CL2021002681A1 (es) Inhibidores de la dihidroorotato deshidrogenasa.
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
NO20070258L (no) Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
EA201200917A1 (ru) Пролекарства ингибиторов плазменного калликреина
MX2022000545A (es) Inhibidores de enzimas.
EA202193019A1 (ru) Лечение наследственного ангионевротического отека
JOP20220227A1 (ar) مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
BR112022003768A2 (pt) Compostos inibidores de perk
MX2025002677A (es) Moduladores de la alfa-1 antitripsina
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
MX2024003015A (es) Nuevos derivados de quinolina.
JOP20230249A1 (ar) مثبطات أروماتية غير متجانسة ثنائية الحلقات لـ klk5
MX2025015694A (es) Compuestos de formamida heteroaromáticos y usos de los mismos en medicina